Key facts
- This page summarizes Robert W. Ross's Form 4 filing for Xilio Therapeutics, Inc. (XLO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2024, 16:30.
Robert W. Ross - 14 Jun 2024 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)
- Reporting relationship
- Director
- Issuer ticker
- XLO
- Reported as of
- 14 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2024, 16:30:15 UTC
- Prior SEC filing
- 08 Sep 2023
- Next SEC filing
- 12 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Julia Walcott, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Robert W. Ross filed Form 4 for Xilio Therapeutics, Inc. (XLO) on 17 Jun 2024.
Change
- Previous filing in this sequence was filed on 08 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XLO
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 14 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $1.02
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
SEC remarks
Exhibit 24 - Power of Attorney